8-K: Clearwater Analytics to Acquire Enfusion for $1.5 Billion, Expanding Investment Management Platform

Clearwater Analytics is set to acquire Enfusion for $1.5 billion in a mix of cash and stock, aiming to create a unified front-to-back platform for investment management.

Summary

• Clearwater Analytics has agreed to acquire Enfusion for $1.5 billion, including the termination of Enfusions tax receivable agreement for $30 million.
• The acquisition aims to create a cloud-native front-to-back platform for the investment management industry.
• Enfusion shareholders will receive $11.25 per share, consisting of $5.85 in cash and $5.40 in Clearwater Class A Common Stock, representing a 13% premium over Enfusion's closing price on January 10, 2025.
• The exchange ratio will be determined at closing with reference to a 10% collar around a Clearwater Class A Common Stock price of $27.79.
• Clearwater expects to pay approximately $760 million in cash and issue between 23 million and 28 million new shares to Enfusion shareholders.
• The transaction is expected to close in Q2 2025, pending shareholder and regulatory approvals.
• Enfusion expects preliminary full year 2024 revenue of approximately $201-202 million, representing 15-16% year on year growth.
• Enfusion expects preliminary Annual Recurring Revenue (ARR) as of December 31, 2024, of approximately $210-211 million, representing 13-14% year on year growth.
• Clearwater has obtained committed financing to support the transaction, which is expected to be funded, together with cash on hand, with a $800 million Term Loan B to fund the transaction and refinance certain existing debt.
• Clearwater has also secured commitments for a $200 million revolving line of credit.
• Gross leverage at closing is expected to be approximately 3.7 times adjusted pro forma EBITDA.

Sentiment

Score: 8

Explanation: The document presents a positive outlook on the acquisition, highlighting strategic benefits, synergy opportunities, and growth potential. The financial details and management commentary support a favorable sentiment.

Positives

• The acquisition creates a front-to-back platform, enhancing Clearwater's capabilities and expanding its TAM by $1.9 billion.
• Enfusion's strong international presence is expected to accelerate Clearwater's global adoption strategy.
• Clearwater anticipates significant synergy opportunities, including accelerated growth for Enfusion and improved unit economics.
• The transaction is expected to deliver 400 bps in Adjusted EBITDA margin expansion in the first year after close and an additional 400 bps in the second year after close.
• The TRA termination payment represents an approximately 78% reduction to the contractual early termination obligation otherwise due under the TRA in connection with a change of control, representing an approximately $105 million benefit to Enfusions shareholders.

Risks

• The transaction is subject to shareholder and regulatory approvals, and customary closing conditions.
• There are risks associated with integrating Enfusion's operations and technology with Clearwater's.
• There are risks associated with retaining and incentivizing Enfusion's employees and retaining Enfusion's clients.
• There are risks associated with repaying debt to be incurred in connection with the Enfusion acquisition and meeting financial covenants to be imposed in connection with such debt.
• There are risks that cost savings, synergies and growth from the acquisition may not be fully realized or may take longer to realize than expected.
• The finalization and audit of Enfusions 2024 fiscal year financial results could potentially result in changes or adjustments to the preliminary financial results presented herein.

Future Outlook

Clearwater expects to accelerate growth and drive improved unit economics at Enfusion, while also growing its emerging managed services business. Clearwater expects to deliver 400 bps in Adjusted EBITDA margin expansion in the first year after close and an additional 400 bps in the second year after close.

Management Comments

• Sandeep Sahai, CEO of Clearwater Analytics, stated that the acquisition will create a unified, cloud-native front-to-back platform and accelerate growth.
• Oleg Movchan, CEO of Enfusion, believes the merger will accelerate and enhance their combined ability to support clients' evolving needs.
• Jim Cox, CFO of Clearwater Analytics, stated that the acquisition will redefine investment management, deliver meaningful efficiencies, and expand their global reach.

Industry Context

This acquisition reflects a trend towards consolidation in the investment management software industry, with firms seeking to offer more comprehensive, integrated solutions to clients. Clearwater's move to add front-office capabilities through Enfusion aligns with this trend.

Comparison to Industry Standards

• BlackRock's Aladdin is a well-known front-to-back platform, and this acquisition positions Clearwater to better compete with such established players.
• Other competitors in the investment management software space include firms like SS&C Technologies, FactSet, and SimCorp.
• The acquisition aims to create a more seamless data management process, addressing a common pain point in the industry where data handoffs between front, middle, and back offices can lead to inefficiencies and errors.

Stakeholder Impact

• Enfusion shareholders will receive a premium for their shares.
• Clearwater clients will benefit from a more comprehensive, integrated platform.
• Enfusion clients will gain access to Clearwater's resources and expertise.
• Employees of both companies may experience changes as a result of the integration.

Next Steps

• Enfusion shareholders need to approve the transaction.
• Regulatory approvals need to be obtained.
• Clearwater and Enfusion will work to integrate their operations and technologies.
• The exchange ratio will be determined at closing with reference to a 10% collar around a Clearwater Class A Common Stock price of $27.79.

Key Dates